Role of radiotherapy to bulky disease in elderly patients with aggressive b-cell lymphoma

Journal of Clinical Oncology

Volumn 32, Issue 11, 2014, Pages 1112-1118

  Held, Gerhard ^a   Murawski, Niels ^a   Ziepert, Marita ^b   Fleckenstein, Jochen ^a   Pöschel, Viola ^a   Zwick, Carsten ^a   Bittenbring, Jörg ^a   Hänel, Mathias ^c   Wilhelm, Sibylla ^d   Schubert, Jörg ^a   Schmitz, Norbert ^e   Löffler, Markus ^b   Rübe, Christian ^a   Pfreundschuh, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c KLINIKUM CHEMNITZ   (Germany)

^d STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^e DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; R CHOP PROTOCOL; R-CHOP PROTOCOL;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; AGGRESSIVE B CELL LYMPHOMA; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; INTENTION TO TREAT ANALYSIS; INTERNATIONAL PROGNOSTIC INDEX; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOLID TUMOR; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84901837261     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.4505     Document Type: Article

References (16)

1. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
2. Pfreundschuh M, Trümper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
3. Pfreundschuh M, Schubert J, Ziepert M, et al: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116, 2008
4. Horning SJ, Weller E, Kim K, et al: Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22:3032-3038, 2004 (Pubitemid 41103714)
5. Bonnet C, Fillet G, Mounier N, et al: CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25:787-792, 2007 (Pubitemid 350002878)
6. Avilés A, Delgado S, Nambo MJ, et al: Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma. Int J Radiat Oncol Biol Phys 30:799-803, 1994 (Pubitemid 24355928)
7. Avilés A, Fernandezb R, Perez F, et al: Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk Lymphoma 45:1385-1389, 2004 (Pubitemid 38701914)
8. Kaplan E, Meier, P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
9. Pfreundschuh M, Kuhnt E, Trümper L, et al: CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12:1013-1022, 2011
10. Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al: Prognostic significance of maximum tumour (bulk) diameter in young patients with goodprognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: An exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 9:435-444, 2008
11. Dunleavy K, Pittaluga S, Maeda LS, et al: Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368:1408-1416, 2013
12. Récher C, Coiffier B, Haioun C, et al: Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial. Lancet 378:1858-1867, 2011
13. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI-sponsored International Working Group. J Clin Oncol 17:1244, 1999
14. Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al: SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 118:37-43, 2011
15. Sehn H, Hoskins P, Klasa R: FDG-PET scan guided consolidatve therapy optimizes outcome in patients with advanced-stage diffuse large B-cell lymphoma with residual abnormalities on CT scan following R-CHOP. Blood 116, 2010 (abstr 372)
16. Dabaja BS, Phan J, Medeiros LJ, et al: Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma 54:2631-2638, 2013